image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 3.06
-3.77 %
$ 19.4 M
Market Cap
-5.37
P/E
1. INTRINSIC VALUE

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.[ Read More ]

The intrinsic value of one NXGL stock under the base case scenario is HIDDEN Compared to the current market price of 3.06 USD, NEXGEL, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NXGL

image
FINANCIALS
4.09 M REVENUE
99.66%
-3.48 M OPERATING INCOME
-3.85%
-3.16 M NET INCOME
33.48%
-3.24 M OPERATING CASH FLOW
-8.16%
4.46 M INVESTING CASH FLOW
179.64%
379 K FINANCING CASH FLOW
110.35%
2.94 M REVENUE
104.17%
-788 K OPERATING INCOME
25.24%
-693 K NET INCOME
21.69%
-1.22 M OPERATING CASH FLOW
-73.71%
-8 K INVESTING CASH FLOW
98.63%
1.21 M FINANCING CASH FLOW
1996.88%
Balance Sheet Decomposition NEXGEL, Inc.
image
Current Assets 5.05 M
Cash & Short-Term Investments 2.7 M
Receivables 633 K
Other Current Assets 1.72 M
Non-Current Assets 4.9 M
Long-Term Investments 0
PP&E 3.35 M
Other Non-Current Assets 1.55 M
Current Liabilities 2.55 M
Accounts Payable 1.23 M
Short-Term Debt 558 K
Other Current Liabilities 758 K
Non-Current Liabilities 2.24 M
Long-Term Debt 2.24 M
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall NEXGEL, Inc.
image
Revenue 4.09 M
Cost Of Revenue 3.47 M
Gross Profit 619 K
Operating Expenses 4.1 M
Operating Income -3.48 M
Other Expenses -320 K
Net Income -3.16 M
RATIOS
15.14% GROSS MARGIN
15.14%
-85.03% OPERATING MARGIN
-85.03%
-77.21% NET MARGIN
-77.21%
-67.21% ROE
-67.21%
-31.71% ROA
-31.71%
-62.82% ROIC
-62.82%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis NEXGEL, Inc.
image
Net Income -3.16 M
Depreciation & Amortization 443 K
Capital Expenditures -696 K
Stock-Based Compensation 217 K
Change in Working Capital -421 K
Others -536 K
Free Cash Flow -3.93 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets NEXGEL, Inc.
image
NXGL has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership NEXGEL, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
125 K USD 5
0-3 MONTHS
0 USD 0
3-6 MONTHS
175 K USD 3
6-9 MONTHS
8.54 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Aug 23, 2024
Bought 25 K USD
Stein John Nachum
Director
+ 10000
2.5 USD
2 months ago
Aug 23, 2024
Bought 25 K USD
glassman steven mark
Director
+ 10000
2.5 USD
2 months ago
Aug 23, 2024
Bought 25 K USD
ZELDIS JEROME B
Director
+ 10000
2.5 USD
2 months ago
Aug 23, 2024
Bought 25 K USD
Henry Scott Robert
Director
+ 10000
2.5 USD
2 months ago
Aug 23, 2024
Bought 25 K USD
Drapczuk Adam E III
Chief Financial Officer
+ 10000
2.5 USD
8 months ago
Mar 01, 2024
Bought 50 K USD
Henry Scott Robert
Director
+ 23697
2.11 USD
8 months ago
Mar 01, 2024
Bought 25 K USD
glassman steven mark
Director
+ 11848
2.11 USD
8 months ago
Mar 01, 2024
Bought 100 K USD
Drapczuk Adam E III
Chief Financial Officer
+ 47394
2.11 USD
10 months ago
Dec 22, 2023
Bought 8.54 K USD
glassman steven mark
Director
+ 3885
2.197 USD
1 year ago
Sep 26, 2023
Bought 4.9 K USD
Stein John Nachum
Director
+ 2500
1.96 USD
1 year ago
Sep 14, 2023
Bought 1.14 K USD
Henry Scott Robert
Director
+ 500
2.27 USD
1 year ago
Sep 13, 2023
Bought 13.5 K USD
Henry Scott Robert
Director
+ 6000
2.2499 USD
1 year ago
Sep 12, 2023
Bought 9.12 K USD
Henry Scott Robert
Director
+ 4000
2.2788 USD
1 year ago
Aug 22, 2023
Bought 1.88 K USD
Henry Scott Robert
Director
+ 980
1.92 USD
1 year ago
Aug 21, 2023
Bought 3.9 K USD
Henry Scott Robert
Director
+ 2000
1.95 USD
1 year ago
Jun 08, 2023
Bought 7.98 K USD
Henry Scott Robert
Director
+ 3558
2.244 USD
1 year ago
Jun 08, 2023
Bought 11.4 K USD
Stein John Nachum
Director
+ 5000
2.28 USD
1 year ago
Jun 07, 2023
Bought 13.4 K USD
Stein John Nachum
Director
+ 5000
2.69 USD
1 year ago
Jun 08, 2023
Bought 2.22 K USD
STEFANSKY DAVID
Director
+ 1000
2.22 USD
1 year ago
Jun 07, 2023
Bought 5 K USD
STEFANSKY DAVID
Director
+ 2000
2.5 USD
1 year ago
Jun 02, 2023
Bought 4.8 K USD
Henry Scott Robert
Director
+ 2000
2.4 USD
1 year ago
May 31, 2023
Bought 2.25 K USD
Henry Scott Robert
Director
+ 1000
2.25 USD
1 year ago
May 31, 2023
Bought 4.84 K USD
STEFANSKY DAVID
Director
+ 2000
2.42 USD
1 year ago
May 30, 2023
Bought 12.6 K USD
STEFANSKY DAVID
Director
+ 5000
2.53 USD
1 year ago
May 30, 2023
Bought 10 K USD
glassman steven mark
Director
+ 4200
2.38 USD
1 year ago
May 26, 2023
Bought 11.7 K USD
ZELDIS JEROME B
Director
+ 5000
2.3377 USD
1 year ago
May 24, 2023
Bought 4.02 K USD
Henry Scott Robert
Director
+ 2000
2.01 USD
1 year ago
May 23, 2023
Bought 1.9 K USD
Henry Scott Robert
Director
+ 1000
1.9 USD
1 year ago
May 22, 2023
Bought 7.8 K USD
Henry Scott Robert
Director
+ 4000
1.95 USD
1 year ago
Dec 19, 2022
Bought 7.95 K USD
STEFANSKY DAVID
Director
+ 5000
1.59 USD
1 year ago
Dec 12, 2022
Bought 10.8 K USD
STEFANSKY DAVID
Director
+ 7500
1.4433 USD
1 year ago
Nov 29, 2022
Bought 3.5 K USD
STEIN NACHUM
Director
+ 3000
1.1667 USD
1 year ago
Nov 25, 2022
Bought 2.4 K USD
STEIN NACHUM
Director
+ 2000
1.2 USD
1 year ago
Nov 23, 2022
Bought 120 USD
STEIN NACHUM
Director
+ 100
1.2 USD
1 year ago
Nov 21, 2022
Bought 2.35 K USD
STEIN NACHUM
Director
+ 2000
1.1733 USD
1 year ago
Nov 29, 2022
Bought 5 K USD
STEIN NACHUM
Director
+ 3000
1.667 USD
1 year ago
Nov 25, 2022
Bought 2.4 K USD
STEIN NACHUM
Director
+ 2000
1.2 USD
1 year ago
Nov 23, 2022
Bought 120 USD
STEIN NACHUM
Director
+ 100
1.2 USD
1 year ago
Nov 21, 2022
Bought 2.35 K USD
STEIN NACHUM
Director
+ 2000
1.1733 USD
2 years ago
Aug 30, 2022
Bought 8.28 K USD
STEFANSKY DAVID
director:
+ 5000
1.656 USD
2 years ago
Aug 30, 2022
Bought 2.77 K USD
Spinrad Yaakov
director:
+ 1648
1.68 USD
2 years ago
Aug 25, 2022
Bought 8.65 K USD
STEFANSKY DAVID
director:
+ 5000
1.73 USD
2 years ago
Aug 16, 2022
Bought 4.48 K USD
STEFANSKY DAVID
Director
+ 2500
1.792 USD
2 years ago
Aug 15, 2022
Bought 5.47 K USD
STEFANSKY DAVID
director:
+ 2872
1.9033 USD
2 years ago
Jun 24, 2022
Bought 4.99 K USD
STEFANSKY DAVID
director:
+ 3128
1.5962 USD
2 years ago
May 27, 2022
Bought 24.5 K USD
Drapczuk Adam E III
Chief Financial Officer
+ 15000
1.6315 USD
2 years ago
Mar 25, 2022
Bought 9.5 K USD
STEIN NACHUM
director:
+ 5000
1.9 USD
2 years ago
Mar 25, 2022
Bought 10 K USD
ZELDIS JEROME B
director:
+ 5300
1.8887 USD
2 years ago
Mar 25, 2022
Bought 10.3 K USD
glassman steven mark
director:
+ 5500
1.87 USD
2 years ago
Dec 27, 2021
Bought 49.9 K USD
ZELDIS JEROME B
Director
+ 9091
5.49 USD
2 years ago
Dec 27, 2021
Bought 9.99 K USD
Toledano Miranda Jayne
Director
+ 1819
5.49 USD
2 years ago
Dec 27, 2021
Bought 154 K USD
STEIN NACHUM
Director
+ 28000
5.49 USD
2 years ago
Dec 27, 2021
Bought 49.9 K USD
STEFANSKY DAVID
Director
+ 9091
5.49 USD
2 years ago
Dec 27, 2021
Bought 27.4 K USD
glassman steven mark
Director
+ 5000
5.49 USD
7. News
NEXGEL, Inc. (NXGL) Q3 2024 Earnings Call Transcript NEXGEL, Inc. (NASDAQ:NXGL ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Maria Honeycutt - Account Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer Adam Drapczuk - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Michael Gustitus - One Pride George Marema - Pareto Adventures Operator Good afternoon, ladies and gentlemen. Welcome to NEXGEL's Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 3 days ago
NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing globenewswire.com - 3 days ago
NEXGEL Announces $2,000,000 Registered Direct Offering LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 727,272 of its shares of common stock and the issuance of warrants to purchase up to an aggregate of 363,636 shares of common stock for a combined offering purchase price of $2.75 per share of common stock in a registered direct offering. The warrants will have an exercise price of $4.25 per share and be exercisable immediately upon issuance and have a term of five years from the date of issuance. globenewswire.com - 5 days ago
NEXGEL to Participate in Upcoming October Investor Conferences LANGHORNE, Pa., Oct. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, is scheduled to participate in the following October 2024 investor conferences. globenewswire.com - 1 month ago
NEXGEL Appoints Kip Crecca to its Scientific Advisory Board LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip Crecca to its Scientific Advisory Board. globenewswire.com - 1 month ago
NEXGEL, Inc. (NXGL) Q2 2024 Earnings Call Transcript NEXGEL, Inc. (NASDAQ:NXGL ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer, President and Director Adam Drapczuk - Chief Financial Officer Conference Call Participants William Odenthal - COVA Capital Partners Eric Ramos - Titan Capital Management Operator Good afternoon. I will be your conference operator today. seekingalpha.com - 3 months ago
NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million LANGHORNE, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record second quarter 2024 revenue of $1.44 million and is reiterating revenue guidance for the 2024 third and fourth quarter of $2.2 million and $2.6 million, respectively. globenewswire.com - 3 months ago
NEXGEL to Report Second Quarter 2024 Financial Results on August 14th Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa. globenewswire.com - 3 months ago
NEXGEL and Innovative Optics US Initiate Institutional Review Board (IRB) Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal The 30-patient study is designed to measure the efficacy of applying NEXGEL's hydrogel during laser hair removal in eliminating harmful particles or plume during treatments globenewswire.com - 4 months ago
NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively LANGHORNE, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced preliminary, unaudited revenue for the second quarter of 2024 and has provided revenue guidance for the third and fourth quarter of 2024. globenewswire.com - 4 months ago
NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America LANGHORNE, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the first product to be distributed under its recently formed partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health. Histasolv®, sold as DAOSIN® in Europe, is Europe's number one selling Diamine Oxidase (‘DAO') enzyme supplement generating well over $10 million in annualized revenue to treat histamine food intolerance, which can cause migraines and headaches, gut issues, and skin conditions. Headquartered in Germany, STADA is one of the fastest growing top ten companies in consumer healthcare and the fourth largest manufacturer in this segment in Europe. globenewswire.com - 5 months ago
NEXGEL Acquires International Beauty Brand, Silly George Acquisition further expands NEXGEL Health, Wellness, and Beauty consumer product portfolio Silly George is on a revenue run rate of approximately $2 million LANGHORNE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the acquisition of Silly George , an international beauty company with specialty in eye and eyelash consumer products and a revenue run rate of approximately $2 million. globenewswire.com - 6 months ago
8. Profile Summary

NEXGEL, Inc. NXGL

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 19.4 M
Dividend Yield 0.00%
Description NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.
Contact 2150 Cabot Boulevard West, Langhorne, PA, 19047 https://nexgel.com
IPO Date Dec. 22, 2021
Employees 19
Officers Mr. Adam R. Levy Chief Executive Officer, President & Director Mr. Adam E. Drapczuk III Chief Financial Officer Mr. Gregory Robb Vice President of Operations